Pfizer Will Unblind Vaccine Trials Based On Local, National Prioritization

Pfizer will move forward with administering its COVID-19 vaccine to placebo recipients -- and thus unblinding its study -- on a rolling basis once the vaccine is available to trial participants’ demographic groups based on federal and state prioritization plans, company officials said, despite FDA’s repeated objections to unblinding vaccine studies immediately after emergency use authorization. FDA, its vaccine advisers, and some consumer and patient advocates have argued that unblinding vaccine studies will cause vaccine makers to lose out on...